619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial
S.N. Westin, Kathleen N Moore, H. S. Chon, Jung-Yun Lee, Jessica Thomes Pepin, M. Sundborg, Joseph de la Garza, S. Nishio, Ke Wang, K. Mcintyre, T. Tillmanns, Fernando Contreras Mejia, Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz, C.A. Papadimitriou, Marta Gil-Martin, B. Brasiuniene, C. Donnelly, Xiaochun Liu, E. Nieuwenhuysen
{"title":"619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial","authors":"S.N. Westin, Kathleen N Moore, H. S. Chon, Jung-Yun Lee, Jessica Thomes Pepin, M. Sundborg, Joseph de la Garza, S. Nishio, Ke Wang, K. Mcintyre, T. Tillmanns, Fernando Contreras Mejia, Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz, C.A. Papadimitriou, Marta Gil-Martin, B. Brasiuniene, C. Donnelly, Xiaochun Liu, E. Nieuwenhuysen","doi":"10.1136/ijgc-2024-esgo.31","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"54 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
